1. Home
  2. SAVA vs HNNA Comparison

SAVA vs HNNA Comparison

Compare SAVA & HNNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAVA
  • HNNA
  • Stock Information
  • Founded
  • SAVA 1998
  • HNNA 1989
  • Country
  • SAVA United States
  • HNNA United States
  • Employees
  • SAVA N/A
  • HNNA N/A
  • Industry
  • SAVA Biotechnology: Pharmaceutical Preparations
  • HNNA Investment Managers
  • Sector
  • SAVA Health Care
  • HNNA Finance
  • Exchange
  • SAVA Nasdaq
  • HNNA Nasdaq
  • Market Cap
  • SAVA 102.4M
  • HNNA 87.1M
  • IPO Year
  • SAVA N/A
  • HNNA N/A
  • Fundamental
  • Price
  • SAVA $2.16
  • HNNA $12.16
  • Analyst Decision
  • SAVA Hold
  • HNNA
  • Analyst Count
  • SAVA 1
  • HNNA 0
  • Target Price
  • SAVA $2.00
  • HNNA N/A
  • AVG Volume (30 Days)
  • SAVA 607.2K
  • HNNA 13.9K
  • Earning Date
  • SAVA 11-06-2025
  • HNNA 08-06-2025
  • Dividend Yield
  • SAVA N/A
  • HNNA 4.52%
  • EPS Growth
  • SAVA N/A
  • HNNA 56.56
  • EPS
  • SAVA N/A
  • HNNA 1.25
  • Revenue
  • SAVA N/A
  • HNNA $35,816,000.00
  • Revenue This Year
  • SAVA N/A
  • HNNA N/A
  • Revenue Next Year
  • SAVA N/A
  • HNNA N/A
  • P/E Ratio
  • SAVA N/A
  • HNNA $9.73
  • Revenue Growth
  • SAVA N/A
  • HNNA 32.04
  • 52 Week Low
  • SAVA $1.15
  • HNNA $8.43
  • 52 Week High
  • SAVA $33.98
  • HNNA $13.88
  • Technical
  • Relative Strength Index (RSI)
  • SAVA 45.76
  • HNNA 58.57
  • Support Level
  • SAVA $2.12
  • HNNA $11.55
  • Resistance Level
  • SAVA $2.40
  • HNNA $13.00
  • Average True Range (ATR)
  • SAVA 0.10
  • HNNA 0.51
  • MACD
  • SAVA -0.01
  • HNNA 0.17
  • Stochastic Oscillator
  • SAVA 17.24
  • HNNA 63.95

About SAVA Cassava Sciences Inc.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

About HNNA Hennessy Advisors Inc.

Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.

Share on Social Networks: